UCB to focus on core business in India

UCB to sell its established brands portfolio in India to Dr. Reddy’s for € 118 million

07-Apr-2015 - In line with its strategic focus, UCB announces it has entered an agreement with Dr. Reddy’s to sell its established brands in India, including its franchises in the areas of allergies and respiratory disorders. The amount of the transaction amounts to INR 8000 million (~ €118 million). The ...

Dr. Reddy's Laboratories intends to make a recommended public offer for OctoPlus N.V.

23-Oct-2012 - Dr. Reddy's and OctoPlus jointly announced that they have reached conditional agreement in connection with an intended public offer by Dr. Reddy's, or a wholly owned subsidiary of Dr. Reddy's, for all issued and outstanding ordinary shares in the capital of OctoPlus at an offer price of € 0.52 ...

Merck and Dr. Reddy’s Laboratories Announce Collaboration to Develop and Commercialize Biosimilars

Combined Biologics expertise of Merck and Dr. Reddy’s to deliver on promise of biosimilars

07-Jun-2012 - Merck and Dr. Reddy’s Laboratories Ltd. announced a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some ...

SoluBest and Dr. Reddy´s Sign Drug Delivery Collaboration to Develop New, Proprietary Formulations

08-Oct-2010 - SoluBest has closed a collaboration agreement with Dr. Reddy's Laboratories Ltd. to develop a new, proprietary formulation of one of SoluBest’s pipeline compound.. In return, SoluBest is eligible to upfront, research and milestone and significant royalty payments. Further financial details have ...

UCB's Keppra patent litigation in the US settled

08-Oct-2007 - UCB announced that it has reached agreement with each of Mylan Laboratories and Mylan Pharmaceuticals, Dr. Reddy's Laboratories and Cobalt Pharmaceuticals to settle pending patent infringement lawsuits in the U.S. District Court for the Northern District of Georgia. These consolidated lawsuits ...

Rheoscience and Dr. Reddy's commence the first Phase III trial of Balaglitazone (DRF 2593)

Balaglitazone is a novel TZD candidate for the treatment of diabetes mellitus

03-Aug-2007 - Rheoscience A/S and Dr. Reddy's Laboratories announced that the first patient has been dosed in a Phase III study with Balaglitazone (DRF2593-307), which is an insulin sensitizer that acts as a partial PPAR (peroxisome proliferator-activated receptor) gamma agonist. The study is the first in a ...